MT Newswires
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
📊
AI Sentiment
Positive
6/10
- Home
- NCNA
NCNA
NuCana plc
as of 12-12-2025 3:17pm EST
$3.83
$0.22
-5.51%
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
Chart Type:
Time Range:
| Founded: | 1997 | Country: | United Kingdom |
| Employees: | N/A | City: | N/A |
| Market Cap: | 7.6M | IPO Year: | 2017 |
| Target Price: | N/A | AVG Volume (30 days): | 63.9K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -30.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.78 - $330.00 | Next Earning Date: | 11-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered NCNA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 69.13%
69.13%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest NuCana plc News
NCNA Breaking Stock News: Dive into NCNA Ticker-Specific Updates for Smart Investing
GlobeNewswire
NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
📊
AI Sentiment
Positive
6/10
Compare NCNA vs Leading Stocks
See how NCNA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "NCNA NuCana plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.